Combination of Aβ clearance and neurotrophic factors as a potential treatment for Alzheimer’s disease
There is no effective drug to treat Alzheimer’s disease (AD), a neurodegenerative disease affecting an estimated 30 million people around the world. Strongly supported by preclinical and clinical studies, amyloid-beta (Aβ) may be a target for developing drugs against AD. Meanwhile, the fact that loc...
Gespeichert in:
| Veröffentlicht in: | Neuroscience bulletin 2013-02, Vol.29 (1), p.111-120 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 120 |
|---|---|
| container_issue | 1 |
| container_start_page | 111 |
| container_title | Neuroscience bulletin |
| container_volume | 29 |
| creator | Lin, Lian-Feng Liao, Min-Jing Xue, Xiao-Yan Zhang, Wei Yan, Li Cai, Liang Zhou, Xiao-Wen Zhou, Xing Luo, Huan-Min |
| description | There is no effective drug to treat Alzheimer’s disease (AD), a neurodegenerative disease affecting an estimated 30 million people around the world. Strongly supported by preclinical and clinical studies, amyloid-beta (Aβ) may be a target for developing drugs against AD. Meanwhile, the fact that localized neuronal death/loss and synaptic impairment occur in AD should also be considered. Neuronal regeneration, which does not occur normally in the mammalian central nervous system, can be promoted by neurotrophic factors (NTFs). Evidence from clinical trials has shown that both Aβ clearance and NTFs are potentially effective in treating AD, thus a new approach combining Aβ clearance and administration of NTFs may be an effective therapeutic strategy. |
| doi_str_mv | 10.1007/s12264-012-1287-6 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5561854</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>23179066</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-f0f06221d2614044efe2f28a7598f74418fee61d4ab83c3bb55e206e4d231643</originalsourceid><addsrcrecordid>eNp9kE9KAzEUxoMotlYP4EZygdEkk0mmG6EU_0HBTfchM_PSpswkJZkKuvIaXsODeAhPYkq16EYIvITvfd_L-yF0TsklJUReRcqY4BmhLKOslJk4QEM6HhdZyWh5mO5C5pkkQg7QSYwrQgSROT9GA5ZTOSZCDNFy6rvKOt1b77A3ePLxjusWdNCuBqxdgx1sgu-DXy9tjY2uex8i1ungte_B9Va3uA-g-y49sPEBT9qXJdgOwufrW8SNjaAjnKIjo9sIZ991hOa3N_PpfTZ7vHuYTmZZzTnrM0MMEYzRhgnKCedggBlWalmMSyM5p6UBELThuirzOq-qogBGBPAm7SR4PkLXu9j1puqgqdOfgm7VOthOh2fltVV_FWeXauGfVFEIWhbbALoLqIOPMYDZeylRW-pqR10l6mpLXYnkufg9dO_4wZwa2K4hJsktIKiV3wSXOPyT-gWSTZFv</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Combination of Aβ clearance and neurotrophic factors as a potential treatment for Alzheimer’s disease</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Lin, Lian-Feng ; Liao, Min-Jing ; Xue, Xiao-Yan ; Zhang, Wei ; Yan, Li ; Cai, Liang ; Zhou, Xiao-Wen ; Zhou, Xing ; Luo, Huan-Min</creator><creatorcontrib>Lin, Lian-Feng ; Liao, Min-Jing ; Xue, Xiao-Yan ; Zhang, Wei ; Yan, Li ; Cai, Liang ; Zhou, Xiao-Wen ; Zhou, Xing ; Luo, Huan-Min</creatorcontrib><description>There is no effective drug to treat Alzheimer’s disease (AD), a neurodegenerative disease affecting an estimated 30 million people around the world. Strongly supported by preclinical and clinical studies, amyloid-beta (Aβ) may be a target for developing drugs against AD. Meanwhile, the fact that localized neuronal death/loss and synaptic impairment occur in AD should also be considered. Neuronal regeneration, which does not occur normally in the mammalian central nervous system, can be promoted by neurotrophic factors (NTFs). Evidence from clinical trials has shown that both Aβ clearance and NTFs are potentially effective in treating AD, thus a new approach combining Aβ clearance and administration of NTFs may be an effective therapeutic strategy.</description><identifier>ISSN: 1673-7067</identifier><identifier>EISSN: 1995-8218</identifier><identifier>DOI: 10.1007/s12264-012-1287-6</identifier><identifier>PMID: 23179066</identifier><language>eng</language><publisher>Heidelberg: Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences</publisher><subject>Alzheimer Disease - metabolism ; Alzheimer Disease - therapy ; Amyloid beta-Peptides - metabolism ; Anatomy ; Anesthesiology ; Animals ; Biomedical and Life Sciences ; Biomedicine ; Human Physiology ; Humans ; Metabolic Clearance Rate - physiology ; Nerve Growth Factors - therapeutic use ; Neurology ; Neurosciences ; Pain Medicine ; Review</subject><ispartof>Neuroscience bulletin, 2013-02, Vol.29 (1), p.111-120</ispartof><rights>Shanghai Institutes for Biological Sciences, CAS and Springer-Verlag Berlin Heidelberg 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-f0f06221d2614044efe2f28a7598f74418fee61d4ab83c3bb55e206e4d231643</citedby><cites>FETCH-LOGICAL-c442t-f0f06221d2614044efe2f28a7598f74418fee61d4ab83c3bb55e206e4d231643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561854/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561854/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23179066$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Lian-Feng</creatorcontrib><creatorcontrib>Liao, Min-Jing</creatorcontrib><creatorcontrib>Xue, Xiao-Yan</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><creatorcontrib>Yan, Li</creatorcontrib><creatorcontrib>Cai, Liang</creatorcontrib><creatorcontrib>Zhou, Xiao-Wen</creatorcontrib><creatorcontrib>Zhou, Xing</creatorcontrib><creatorcontrib>Luo, Huan-Min</creatorcontrib><title>Combination of Aβ clearance and neurotrophic factors as a potential treatment for Alzheimer’s disease</title><title>Neuroscience bulletin</title><addtitle>Neurosci. Bull</addtitle><addtitle>Neurosci Bull</addtitle><description>There is no effective drug to treat Alzheimer’s disease (AD), a neurodegenerative disease affecting an estimated 30 million people around the world. Strongly supported by preclinical and clinical studies, amyloid-beta (Aβ) may be a target for developing drugs against AD. Meanwhile, the fact that localized neuronal death/loss and synaptic impairment occur in AD should also be considered. Neuronal regeneration, which does not occur normally in the mammalian central nervous system, can be promoted by neurotrophic factors (NTFs). Evidence from clinical trials has shown that both Aβ clearance and NTFs are potentially effective in treating AD, thus a new approach combining Aβ clearance and administration of NTFs may be an effective therapeutic strategy.</description><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer Disease - therapy</subject><subject>Amyloid beta-Peptides - metabolism</subject><subject>Anatomy</subject><subject>Anesthesiology</subject><subject>Animals</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Human Physiology</subject><subject>Humans</subject><subject>Metabolic Clearance Rate - physiology</subject><subject>Nerve Growth Factors - therapeutic use</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Pain Medicine</subject><subject>Review</subject><issn>1673-7067</issn><issn>1995-8218</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE9KAzEUxoMotlYP4EZygdEkk0mmG6EU_0HBTfchM_PSpswkJZkKuvIaXsODeAhPYkq16EYIvITvfd_L-yF0TsklJUReRcqY4BmhLKOslJk4QEM6HhdZyWh5mO5C5pkkQg7QSYwrQgSROT9GA5ZTOSZCDNFy6rvKOt1b77A3ePLxjusWdNCuBqxdgx1sgu-DXy9tjY2uex8i1ungte_B9Va3uA-g-y49sPEBT9qXJdgOwufrW8SNjaAjnKIjo9sIZ991hOa3N_PpfTZ7vHuYTmZZzTnrM0MMEYzRhgnKCedggBlWalmMSyM5p6UBELThuirzOq-qogBGBPAm7SR4PkLXu9j1puqgqdOfgm7VOthOh2fltVV_FWeXauGfVFEIWhbbALoLqIOPMYDZeylRW-pqR10l6mpLXYnkufg9dO_4wZwa2K4hJsktIKiV3wSXOPyT-gWSTZFv</recordid><startdate>20130201</startdate><enddate>20130201</enddate><creator>Lin, Lian-Feng</creator><creator>Liao, Min-Jing</creator><creator>Xue, Xiao-Yan</creator><creator>Zhang, Wei</creator><creator>Yan, Li</creator><creator>Cai, Liang</creator><creator>Zhou, Xiao-Wen</creator><creator>Zhou, Xing</creator><creator>Luo, Huan-Min</creator><general>Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20130201</creationdate><title>Combination of Aβ clearance and neurotrophic factors as a potential treatment for Alzheimer’s disease</title><author>Lin, Lian-Feng ; Liao, Min-Jing ; Xue, Xiao-Yan ; Zhang, Wei ; Yan, Li ; Cai, Liang ; Zhou, Xiao-Wen ; Zhou, Xing ; Luo, Huan-Min</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-f0f06221d2614044efe2f28a7598f74418fee61d4ab83c3bb55e206e4d231643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer Disease - therapy</topic><topic>Amyloid beta-Peptides - metabolism</topic><topic>Anatomy</topic><topic>Anesthesiology</topic><topic>Animals</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Human Physiology</topic><topic>Humans</topic><topic>Metabolic Clearance Rate - physiology</topic><topic>Nerve Growth Factors - therapeutic use</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Pain Medicine</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Lian-Feng</creatorcontrib><creatorcontrib>Liao, Min-Jing</creatorcontrib><creatorcontrib>Xue, Xiao-Yan</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><creatorcontrib>Yan, Li</creatorcontrib><creatorcontrib>Cai, Liang</creatorcontrib><creatorcontrib>Zhou, Xiao-Wen</creatorcontrib><creatorcontrib>Zhou, Xing</creatorcontrib><creatorcontrib>Luo, Huan-Min</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuroscience bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Lian-Feng</au><au>Liao, Min-Jing</au><au>Xue, Xiao-Yan</au><au>Zhang, Wei</au><au>Yan, Li</au><au>Cai, Liang</au><au>Zhou, Xiao-Wen</au><au>Zhou, Xing</au><au>Luo, Huan-Min</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination of Aβ clearance and neurotrophic factors as a potential treatment for Alzheimer’s disease</atitle><jtitle>Neuroscience bulletin</jtitle><stitle>Neurosci. Bull</stitle><addtitle>Neurosci Bull</addtitle><date>2013-02-01</date><risdate>2013</risdate><volume>29</volume><issue>1</issue><spage>111</spage><epage>120</epage><pages>111-120</pages><issn>1673-7067</issn><eissn>1995-8218</eissn><abstract>There is no effective drug to treat Alzheimer’s disease (AD), a neurodegenerative disease affecting an estimated 30 million people around the world. Strongly supported by preclinical and clinical studies, amyloid-beta (Aβ) may be a target for developing drugs against AD. Meanwhile, the fact that localized neuronal death/loss and synaptic impairment occur in AD should also be considered. Neuronal regeneration, which does not occur normally in the mammalian central nervous system, can be promoted by neurotrophic factors (NTFs). Evidence from clinical trials has shown that both Aβ clearance and NTFs are potentially effective in treating AD, thus a new approach combining Aβ clearance and administration of NTFs may be an effective therapeutic strategy.</abstract><cop>Heidelberg</cop><pub>Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences</pub><pmid>23179066</pmid><doi>10.1007/s12264-012-1287-6</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1673-7067 |
| ispartof | Neuroscience bulletin, 2013-02, Vol.29 (1), p.111-120 |
| issn | 1673-7067 1995-8218 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5561854 |
| source | MEDLINE; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Alzheimer Disease - metabolism Alzheimer Disease - therapy Amyloid beta-Peptides - metabolism Anatomy Anesthesiology Animals Biomedical and Life Sciences Biomedicine Human Physiology Humans Metabolic Clearance Rate - physiology Nerve Growth Factors - therapeutic use Neurology Neurosciences Pain Medicine Review |
| title | Combination of Aβ clearance and neurotrophic factors as a potential treatment for Alzheimer’s disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T11%3A25%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20of%20A%CE%B2%20clearance%20and%20neurotrophic%20factors%20as%20a%20potential%20treatment%20for%20Alzheimer%E2%80%99s%20disease&rft.jtitle=Neuroscience%20bulletin&rft.au=Lin,%20Lian-Feng&rft.date=2013-02-01&rft.volume=29&rft.issue=1&rft.spage=111&rft.epage=120&rft.pages=111-120&rft.issn=1673-7067&rft.eissn=1995-8218&rft_id=info:doi/10.1007/s12264-012-1287-6&rft_dat=%3Cpubmed_cross%3E23179066%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/23179066&rfr_iscdi=true |